Drug-induced hepatotoxicity is a major issue for drug development, and toxicogenomics has the potential to predict toxicity during early toxicity screening. A bead-based Illumina oligonucleotide microarray containing 550 liver specific genes has been developed. We have established a predictive screening system for acute hepatotoxicity by analyzing differential gene expression profiles of well-known hepatotoxic and non-hepatotoxic compounds. Low and high doses of tetracycline, carbon tetrachloride, 1-naphthylisothiocyanate, erythromycin estolate, acetaminophen or chloroform as hepatotoxicants, clofibrate, theophylline, naloxone, estradiol, quinidine or dexamethasone as non-hepatotoxic compounds, were administered as a single dose to male Sprague Dawley rats. After 6h, 24h and 72h, livers were taken for histopathological evaluation and for analysis of gene expression alterations. All hepatotoxic compounds tested generated individual gene expression profiles. Based on leave-one-out cross-validation analysis, gene expression profiling allowed the accurate discrimination of all model compounds, 24h after high dose treatment. Even during the regeneration phase, 72h after treatment, carbon tetrachloride, 1-naphthylisothiocyanate and acetaminophen were predicted to be hepatotoxic, and only these three compounds showed histopathological changes at this time. Furthermore, we identified 64 potential marker genes responsible for class prediction, which reflected typical hepatotoxicity responses. These genes and pathways, commonly deregulated by hepatotoxicants, may be indicative of the early characterization of hepatotoxicity and possibly predictive of later hepatotoxicity onset. Two unknown test compounds were used for pre-validating the screening test system, with both being correctly predicted. We conclude that focussed gene microarrays are sufficient to classify compounds with respect to toxicity prediction.
Introduction
Toxicology testing is central for the safety of drug development candidates. Indeed, adverse drug effects are still a major reason for drug withdrawal from the market. Hence, new powerful techniques are needed to improve the detection of potentially toxic compounds from the drug development process earlier. Toxicogenomics, which makes use of DNA microarray technologies and measures the expression of thousands of genes simultaneously, has the potential to revolutionise toxicology. It has been used as a tool to elucidate mechanisms and to predict toxicity (Duggan et al. 1999; Hamadeh et al. 2002) . The advanced knowledge of gene expression patterns together with modern classification algorithms has demonstrated practical benefits for predicting pathological events and toxic endpoints (Steiner et al. 2004; Waring et al. 2001) . Thus, this gain of information can potentially reduce the duration of preclinical toxicology studies and consequently the number of animals needed. Additionally, regulatory agencies are encouraging the use of modern molecular techniques, such as animal or computer-based predictive models and safety biomarkers, to improve predictability and efficiency from laboratory concept to commercial product. In fact, the FDA recognizes the importance in pharmacogenomics and encourages its use in drug development and has released guidance documents for submission (http://www.fda.gov/cder/genomics/).
Predictive toxicology relies mainly on class prediction, whose methods are based on the assumption that gene expression profiles of known toxins from representative toxicological classes (model compounds) can predict the toxicological effects of unknown compounds based on similarities between gene expression profiles (Maggioli et al. 2006; Schena et al. 1995) . Thus, gene expression data can provide an early indication of toxicity because toxinmediated changes in gene expression are often detectable before clinical chemistry, histopathology, or clinical observations (Ulrich and Friend 2002) . Thomas et al. (2001) published one of the first classification algorithms used for the accurate prediction of 24 model compounds based on leave-one-out cross-validation of a large microarray database. Hamadeh et al. (2002) used discrimination algorithms to classify blind samples based on a training set using high density gene expression profiles. Steiner et al. (2004) used support vector machine (SVM) to obtain an optimal discrimination between hepatotoxic and non-hepatotoxic compounds (based on 26 toxic compounds) with their whole genome Affymetrix microarray profiles. These studies varied in experimental design (e.g., time of dosage and number of compounds investigated), but all indicated the potential of toxicogenomics in predictive toxicological risk assessment.
Due to the demand for cheaper, higher throughput screening systems for toxicity testing, as well as the relatively high costs of high density arrays, the question arises whether a microarray focussed on toxicologically relevant genes could also be predictive. Therefore, we established an oligonucleotide microarray with 550 genes, chosen based on their known involvement in hepatotoxicity (published information and internal Merck KGaA bioinformatic data from previous studies), to aid in the classification and risk assessment of acute hepatotoxicity. Our customized focussed microarray was designed using the oligonucleotide Sentrix BeadChips (Illumina Inc.) based on the BeadArray TM technology (Gunderson et al. 2004; Steemers and Gunderson 2005) .
Due to the fact that the liver is the primary site for drug metabolism and hepatotoxicity is one of the most frequently reported human adverse drug reactions, we concentrated on the prediction of hepatotoxicity. Thus, 12 model compounds, including 6 well known hepatotoxicants, were chosen based on an extensive literature study, namely carbon tetrachloride, chloroform, both inducers of necrosis and steatosis (Brattin et al. 1985; Minami et al. 2005; Wang et al. 1997; Weber et al. 2003; Yamamoto et al. 2006) , 1-naphthylisothiocyanate (ANIT) a well known cholestasis inducer (Krell et al. 1982; Mehendale et al. 1994; Orsler et al. 1999) , the antibiotics tetracycline and erythromycin estolate which cause steatosis and cholestasis, respectively (Amacher and Martin 1997; de Longueville et al. 2003; Fromenty and Pessayre 1995; Garcia Monzon et al. 1985; Venkateswaran et al. 1998; Yamamoto et al. 2006 ) and the drug acetaminophen, a well known hepatotoxicant causing liver necrosis (James et al. 2003; Minami et al. 2005; Prescott 1980; Yamamoto et al. 2006) . As non-acute rodent hepatotoxicants the drugs clofibrate (PPAR-agonist) (Corton et al. 2000; Richert et al. 2003; Yadetie et al. 2003) , theophylline (diuretic), naloxone (analgesic), estradiol (estrogen), quinidine (antiarrhythmic) and dexamethasone (corticosteroid) were chosen.
The primary goal of the current paper was to determine whether gene expression based on a relative small set of genes could discriminate between animals acutely treated with various model compounds known to cause hepatotoxicity or with non-hepatotoxic compounds at different time points and dose levels. Such a discriminatory model maybe used for the early characterization of potential hepatotoxicants and maybe for the prediction of chronic hepatotoxic endpoints. Above all, in respect to the 3Rs concept, this would mean significant reduction in animal usage due to the performance of shorter-term studies for the early classification of novel untested compounds.
Materials and Methods

Animal treatment
Tissue samples, used for transcription profiling, were derived from studies using albino 
Histopathology
Histopathological examinations of the liver section from all animals of the 72h groups, stained with haematoxylin and eosin (H&E), were conducted by PHASE 1, Inc. The observed liver alterations were scored and categorised (table 2) .
RNA Isolation and analysis
Total RNA from liver samples (50-90 mg) was isolated using TRI REAGENT (Sigma-Aldrich
Inc., Saint Louis, MO) according to the manufacture's instruction. In addition, after the ethanol precipitation step in the extraction procedure, a cleanup step using the QIAGEN RNeasy Mini kit columns (Qiagen GmbH, Hilden, Germany) was performed to obtain a better yield for later in vitro transcription labelling. The quality of total RNA was checked by gel analysis using the total RNA Nano chip assay on an Agilent 2100 Bioanalyzer (Agilent Technologies GmbH, Berlin, Germany). RNA concentrations were determined using the NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Probe labelling and Illumina Sentrix BeadChip array hybridization
Biotin-labelled cRNA samples for hybridization on custom Illumina Sentrix BeadChip arrays (Illumina Inc., San Diego, CA) were prepared according to Illumina's recommended sample labelling procedure based on the modified Eberwine protocol (Eberwine et al. 1992) . In brief, 500 ng total RNA was used for cDNA synthesis, followed by an amplification/labelling step (in vitro transcription) to synthesize biotin-labelled cRNA according to the MessageAmp II aRNA Amplification kit (Ambion Inc., Austin, TX), with the following modifications requested by Illumina: standard reactions were cut down to ¼ size, separate annealing step of the T7 oligo(dT) primer was omitted (single step of the first-strand cDNA synthesis) and cleanup columns were replaced. QIAquick PCR Purification kit and QIAGEN RNeasy Mini kit (Qiagen), used according to the manufacture's recommendations, were used for cDNA purification (elution with water instead of buffer EB) and for cRNA purification (elution two times with 50 µl water), respectively. Biotin-16-UTP was purchased from PerkinElmer Life and Analytical Sciences, Boston, MA. Due to a reduced amount of standard reactions, total RNA and purified cDNA were dried down and then dissolved in synthesis solutions. The column-purified cRNA was quality controlled using the mRNA Nano Chip Assay on an Agilent 2100 Bioanalyzer and spectrophotometrically quantified (NanoDrop).
Five hundred nanogram amplified biotin-labelled cRNA was then prepared in a solution of BeadChips were washed a second time in diluted Wash E1BC buffer for 5 min, dried immediately after removal by centrifugation at 275g for 4 min at 25°C and scanned.
Focussed Illumina BeadChip microarray analysis
Data acquisition
The focused Sentrix Illumina BeadChips, with each BeadChip comprising 8 microarrays on a glass slide, were scanned at a wavelength of 532 nm and 5µm resolution on the GenePix Gunderson et al. 2004 ). The decoding process, which uses a molecular address, is part of the array manufacture procedure and provides a quality control for all elements of every array (Gunderson et al. 2004) . Subsequently, bead signal intensity extraction, using the imaging and data extraction software, AnEx (Illumina Inc.), was performed prior to further analysis. The focussed Illumina microarrays contain about 1,500 unique probe sequences (Probe ID), or bead types (two 50mer oligonucleotide probes/gene), corresponding to 550 annotated rat genes and several control genes (Gene ID). Each probe sequence is represented by approximately 30 beads on each array and each bead contains more than 10 5 copies of unique covalently attached oligonucleotide probes (Gunderson et al. 2004; Steemers and Gunderson 2005) . Using AnEx, the intensities of all beads (~30) were condensed to an average intensity value per probe ID and then further condensed to one signal intensity value per Gene ID. This is associated with a detection p-value calculated from the background, characterized by the chance that the target sequence signal was distinguishable from the negative controls. Gene IDs with detection values > 0.99 were designated as reliable.
Array quality
Focussed Illumina microarray quality was determined by image viewing and incorporated control bead analysis (housekeeping, hybridization, signal generation, and background).
Arrays with overall intensity outliers from the majority of arrays (caused by poor hybridization conditions or poor imaging) were excluded from further analysis. Fourteen housekeeping genes were used to check the intactness of the biological sample. Hybridization controls covering (A) three concentrations (low, medium, and high) of Cy3-labelled oligonucleotides present in the Hyb E1 buffer were used to yield a gradient hybridization response signal independent of both the cellular RNA quality and success of the sample preparation reactions (six probes), (B) Cy3-labelled probes, including a mismatch oligonucleotide with two single base changes (each), to control for non-specific hybridization (four probes) and (C) Cy3-labelled oligonucleotide target with a high G-C content to check the stringency grade probes of random sequences selected to have no corresponding targets in the rat genome were used to define a background signal, representing the image system background as well as any signal resulting from non-specific binding of dye or cross-hybridization.
Normalization
Quality controlled focussed Illumina microarrays were "chip-wise" normalized using the rank invariant algorithm (Kuhn et al. 2004) and resulting data further analyzed using the Expressionist Analyst software (GeneData, Basel, Switzerland). Briefly, a second normalization of all microarrays over all gene signal intensities based on the arithmetic mean was performed. Comparative analysis between control and treated samples was done separately for each individual compound, including fold change (average signal intensity treated/average signal intensity control) and a significance value (p-value), calculated using a two-tailed, unpaired t-test. A p-value less than 0.05 was accepted as significant. In addition, the False Discovery Rate (FDR, Benjamini-Hochberg q-value) was determined and included into table 3 to improve the relevance of these significantly deregulated genes.
Modelling/Classification
For Support Vector Machine (SVM) classification, implemented in the cross validation tool of Expressionist Analyst software, only normalized intensity values of the treated samples were considered. The samples were categorized as either hepatotoxic or non-hepatotoxic and further sub-categorised into the time and dose. A linear kernel and a penalty of ten were chosen as the parameters for the SVM algorithm. The leave-one-out cross validation scheme with 12 repeats (representing the number of compounds) was used for a robust discrimination. Genes for final discrimination between hepatotoxicity and non-hepatotoxicity were identified by gene ranking Analysis of Variance (ANOVA). Molecular functions of the genes were individually annotated by using the classification schemes in Gene Ontology, KEGG database (keg.org) and MetaCore TM 3.1 software (GeneGO Inc., St. Joseph, MI).
Real-time PCR
All RNA samples from the high dose 24h animals and their corresponding time matched vehicle controls were used to verify 13 genes (table 1) with different biological functions, chosen from the pool of discriminative genes. Since classification models for discrimination analysis do not primarily select either significant and/or genes with pronounced fold changes from either hepatotoxicants or non-hepatotoxic compounds as discriminative gene, the acute phase gene Metallothionein 1a (Mt1a) was added as it showed distinct deregulation by many of the compounds (similar to a positive control). Two housekeeping genes, 18S rRNA and B2m, were run in parallel. Table 1 2.6.1 cDNA synthesis and analysis One microgram total RNA was reverse transcribed to cDNA using random hexamer primers with the first strand cDNA synthesis kit for RT-PCR (AMV) (Roche, Mannheim, Germany) according to the manufacturer's instructions. The quality and quantity of cDNA was determined using the Agilent Bioanalyzer 2100 together with the mRNA Pico Assay (Agilent Technologies, Waldbronn, Germany) according to the manufacturer's instructions.
TaqMan ® Low density array
Real-time PCR analysis was performed using TaqMan ® Low Density Arrays (Applied Biosystems, Darmstadt, Germany). Real-time PCR primers and probes ("TaqMan ® Gene
Expression Assays") for the rat genes listed in Mastermix Plus (Eurogentec, Seraing, Belgium), in a total volume of 100 µl, were loaded per sample loading port. Thermal cycling and fluorescence detection was performed on Applied Biosystems ABI Prism 7900HT Sequence Detection System with ABI Prism 7900HT SDS Software 2.1. Forty-five cycles were run with the following parameters: 2 min at 50 C, 10 min at 94.5 C and for each cycle 30 s at 97 C for denaturation and 1 min at 59.7 C for transcription. Analysis of gene expression values was performed using the efficiencycorrected comparative C T (threshold-cycle) method, determining target gene expression relative to either 18S rRNA or B2m endogenous control expression and relative to the control sample. Real-time PCR efficiencies for the above-mentioned assays were determined by performing the reaction with a dilution series of cDNA (100 ng, 10 ng, 1 ng and 0.1 ng per sample loading port) prepared from control rat liver total RNA. Efficiency values and gene expression ratios were calculated as previously described by (Tuschl and Mueller 2006) . 
Results
Animal testing and histopathology
After exposure to all non-hepatotoxicants as well as the unknown compound B (UNC B), no histopathological alterations were found. On the other hand CCL4, ANIT and AAP showed histopathological changes 72h after treatment. CCL4 showed mild liver cell necrosis at low doses that increased to severe liver cell damage combined with secondary inflammatory and minimal regenerative/proliferative effects after high dose administration. Histopathological changes of ANIT and AAP were restricted to high dose exposure and consisted of minimal liver cell necrosis. In addition, ANIT showed minimal secondary inflammatory and regenerative effects as well as moderate bile duct hyperplasia. The unknown compound A (UNC A) showed minimal liver cell necrosis and inflammation at low level exposure and increased to moderate liver cell damage combined with mild secondary effects.
Histopathology evaluation is summarized in table 2. Table 2 
Principal component analysis of model compounds
In order to detect acute hepatotoxic effects of model compounds on the gene expression level, total RNA from rat livers given a single low or high dose of compound was isolated 6h, 24h and 72h after administration.
The unsupervised method, Principal Component Analysis (PCA), is suited to separate natural subpopulations in an unbiased manner. To determine whether gene expression could separate samples treated with model hepatotoxic compounds at different time points and dose levels, PCA was used to visualize sample distribution. PCA analyses were conducted on all 550 genes on the microarray. Figure 1 shows all 12 compounds, including, time matched vehicle controls (yellow), non-hepatotoxic (blue) and hepatotoxic compounds (others) 6h, 24h and 72h after high dose treatment. Distinct separation of most However, the hepatotoxicants ANIT and CCL4 were separated from the other experiments even 72h after high dose treatment. It is clear from Figure 1 that the TET experiments behaved differentially to the others (based on PCA). Even so, at 24h TET treated animals showed a different gene expression than the corresponding vehicle control animals. By 72h this was no longer the case. 
Common effects of hepatotoxic compounds
Gene expression profiles of all hepatotoxic and non-hepatotoxic compounds with a fold change deregulation of more than 1.5 and p<0.05 were taken to find common significantly deregulated genes. Only at one condition, 24h high dose treatment 5 genes were found to be deregulated by all six hepatotoxicants and not non-hepatotoxicants (table 3) 10 or 1.6-3 fold. Abcb11, which is involved in transporter activity, was significantly downregulated by all hepatoxicants except for ANIT which showed significant diametrical regulation of 1.8 fold. The oxidative stress enzyme, Txnrd1, was significantly up-regulated by hepatotoxic compounds except for EE, which showed a small but significant down-regulation 24h after high dose treatment. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Discrimination between hepatotoxic and non-hepatotoxic compounds
"Leave-one-out" cross-validation (via SVM) using all 550 genes was performed for all normalized treated samples from all 12 compounds to distinguish between hepatotoxic and non-hepatotoxic model compounds. In figure 2, tile plots show that 6h after high dose administration several compounds were misclassified (misclassification rate 58.3%).
However, 24h after high dose treatment gene expression profiles allowed the correct classification of all compounds. After 72h all non-hepatotoxic compounds were correctly predicted and three of the hepatotoxic compounds were predicted to be non-hepatotoxic (misclassification rate 25%). Only AAP, ANIT and CCL4 were predicted to be hepatotoxic 72h after administration. Gene expression profiles obtained from low dose administration of all 12 compounds were incorrectly predicted at all time point (misclassification rates of 66.7% (6h), 50% (24h), 66.7% (72h) were obtained). 
Gene ranking analysis
The ANOVA ranking method analysis was used to achieve a gene set which was responsible for the correct discrimination between hepatotoxic and non-hepatotoxic model compounds 24h after high dose treatment (see 3.4). The best performance concerning the optimal gene set with a misclassification rate of 0% (with which to perform the classification) was reached with a classifier based on 64 genes. In table 4 the top-scoring 64 genes are described. In figure 3 , the gene expression changes of the 24h samples from high dose CCL4 treated rats are shown as an example and data from all 12 compounds summarized in parentheses in 
Verification of the predictive screening test system by two unknown compounds
The possibility that gene expression profiles could classify an unknown compound was tested using the aforementioned model compounds as a training set. Samples derived from rats acutely exposed to two unknown compounds (UNC A and B) for 24h were taken for gene expression analysis on Illumina microarrays and then compared to the model previously described. UNC A was predicted to be hepatotoxic, UNC B as non-hepatotoxic (figure 4). As UNC A bromobenzene was used, an industrial chemical, which is known to cause hepatotoxicity by induction of liver necrosis (Heijne et al. 2004; Lau and Monks 1988) .
The histopathological findings of UNC A were scored and categorized (table 2) .
Bromobenzene showed minimal liver damage at the low dose level that increased to moderate liver cell necrosis with mild secondary effects after high dose treatment. UNC B was an internal Merck KGaA compound, which did not show abnormal histopathological changes on day 1 (table 2) . According to the study design, UNC B was dosed daily for 14 days, and livers showed histopathological changes, including massive bridging liver necrosis with inflammatory bile duct lesions, only after 14 days. 
Discussion
The main focus of this study was to determine whether gene expression of a relatively small set of genes, known or suspected to be involved in hepatotoxicity, could discriminate between known hepatotoxic and non-hepatotoxic compounds. The ultimate goal would be to establish a predictive system for acute hepatotoxicity. Twelve compounds were evaluated at 6h, 24h and 72h and the expression profiles of the six hepatotoxicants could be differentiated from the six non-hepatotoxicants. By using bioinformatic cross-validation approaches and gene ranking analysis, characteristic genes were extracted and functionally classified. Only samples after high dose administration showed predictive results. Low dose treatment showed no discriminative patterns, which correlated well with the histopathological observations in these animals.
Effects of hepatotoxic compounds
All 6 hepatotoxic compounds showed individual gene expression profiles, reflecting compound specific differences at the molecular level (data not shown). After 24h high dose treatment only 5 genes were commonly deregulated by these hepatotoxicants. The xenobiotic metabolism enzyme Fmo1 increases solubility and thereby ensures rapid excretion of xenobiotics (Eswaramoorthy et al. 2006) . Its down-regulation may contribute to hepatotoxicity due to lack of elimination and emphasizes the importance of xenobiotic metabolism. The down-regulation of Maob, which catalyzes the oxidative deamination of biogenic and xenobiotic amines (Zhou et al. 1995) , further supports this. The differences in fold change levels of these commonly deregulated genes, can also be a sign that different maximal toxic time points exist, for example, 6h for CCL4 and 12h for AAP (Minami et al. 2005) . The carbohydrate metabolism enzyme Pygl, was down-regulated by all hepatotoxicants indicating a decrease in glycogenolysis, since it catalyzes the first step in glycogen degradation (Bollen et al. 1998) . This could indicate a lack of resourcing energy, correlating with depleted glycogen stores which is seen histopathologically. Txndr1 is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 involved in protecting cells from oxidative stress (Deroo et al. 2004; Neumann et al. 2003) . Its up-regulation indicates the generation of reactive oxygen species, potentially contributing to DNA and protein damage. Txnrd1 is known to be up-regulated by typical hepatotoxicants such as bromobenzene, thioacetamide, CCL4 and AAP (Minami et al. 2005; Moto et al. 2005) and is a sign of general cytotoxicity in the liver. Abcb11 plays a major role in the hepatobiliary excretion of bile salts (Strautnieks et al. 1998) . Down-regulation by hepatotoxicants could result in severe hepatic effects, including intrahepatic cholestasis (Hirano et al. 2006 ) and hepatic steatosis (Figge et al. 2004) .
Discrimination of hepatotoxicants and non-hepatotoxicants
Some of the non-hepatotoxicants also showed unique profiles. For example, clofibrate is well-known to cause hepatocarcinogenesis (Baldwin et al. 1980; Corton et al. 2000) , however, in our short-term study clofibrate was expected and shown to be non-hepatotoxic.
At the gene expression level only typical PPAR-alpha mediated responses were observed (Corton et al. 2000; Richert et al. 2003) .
A subset of gene expression profiles was defined that allowed an accurate prediction of hepatotoxicity. This was seen in particular 24h after high dose treatment, reflecting the time point where most pronounced and characteristic deregulations occurred. At 6h the high misclassification rate (58.3%) can probably be attributed to early stress responses caused by intraperitoneal dosing, immune responses and animal handling. At 72h, the model correctly classified only 3 of the hepatotoxic compounds. This may be an indication of the regeneration effects that have occurred after a single treatment (Mehendale 2005) . The PCA showed that most compounds moved towards the main cluster, suggesting similar gene expression profiles. This is probably due to effective removal of the substance via metabolism and excretion, allowing the liver to recover. The 3 compounds, AAP, ANIT and CCL4, predicted to be hepatotoxic after 72h, show the severity of hepatotoxicity of these compounds. Their distinct lasting effects on gene expression correlated very well with the histopathological findings taken at 72h (only these 3 compounds showed histopathological changes). Interestingly, ANIT was predicted to be hepatotoxic only after 24h and 72h and at 6h was predicted to be non-hepatotoxic. This is consistent with the publication of Orsler et al.
(1999) who showed that histopathological changes after administration of ANIT to rats were observed only after 10-15 h. AAP was correctly predicted to be hepatotoxic at all time points, which emphasises the fact that AAP is a potent, acute hepatotoxicant. This study is in concordance with Huang et al. (2004) , who demonstrated that a dose of 4500 mg/kg AAP induced a distinct gene expression profile, which related directly to its hepatotoxicity.
The most distinct gene expression changes were observed after CCL4 exposure. This corresponds very well with the severe liver cell damage with secondary inflammation and regenerative/proliferation effects, which was seen histopathologically. The data support the fact that the estimated maximal toxic time point, based on gene expression profiles, was 6h (Minami et al. 2005) .
General comments to the predictive test system for hepatotoxicants
It is worth noting that to establish this screening system, outbred rats were used to deliberately reflect the biological variance of animals within a certain range of genetic polymorphisms. This reflects better the normal human situation. Furthermore, the predictive test system demonstrated a certain robustness since the discrimination between hepatotoxic and non-hepatotoxic compounds was possible regardless of the different hepatotoxic characteristics (cholestasis, steatosis or necrosis). The use of leave-one-out cross-validation on the one hand and the consideration that the data set of a model compound is composed of biological replicates (technical replicates were condensed) on the other hand indicate a robust test system, suggesting a potential application in the prediction of untested compounds.
Top-scoring genes for class prediction after 24h
Twenty four hours after high dose treatment the best discrimination between hepatotoxicants and non-hepatotoxicants was achieved by the leave-one-out cross-validation method. Sixty 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 four genes (table 4) were found to be responsible for this class prediction and reflected typical hepatotoxicity responses. The rank order is characterized by genes with different biological function/toxicological relevance. The top-scored gene Pygl was significantly downregulated only by hepatotoxicants corroborating the suggestion that Pygl could be an appropriate hepatotoxicity safety marker. The second highest scoring gene, tumor necrosis factor receptor superfamily member 1a (Tnfrsf1a), plays an important role in apoptosis by mediating TNF signalling, whose over expression in acute disease states can lead to liver injury (Mohammed et al. 2004; Volpes et al. 1992; Yamada et al. 1998) . Keratin complex 1 acidic gene 18 (Krt1-18) forms intermediate filaments in liver (Oshima et al. 1996) . Disruption or absence of keratins in the liver can lead to mild hepatitis and increased sensitivity to hepatotoxins (Baribault et al. 1994; Ku et al. 1996) . Caulin et al. (2000) found that increases in Krt1-18 can resist TNF-induced apoptosis, suggesting Krt1-18 is involved in liver regeneration.
Page 20 of 43 Toxicological Sciences
In general, the top scoring genes showed the most pronounced deregulation in many biological categories, such as Phase 1 and 2 xenobiotic metabolism, lipid metabolism and cell proliferation. Disturbances in lipid metabolisms occurred by down-regulation of genes such as ATP citrate lyase (Acly), which has an important role in supplying acetyl-CoA for both cholesterogenesis and lipogenesis (Pearce et al. 1998 ). Therefore, lipid biosynthesis level in the liver is low, suggesting low energy resources which may contribute to the pathogenesis of liver damage (Beigneux et al. 2004) . The DNA damage response gene growth arrest and DNA-damage-inducible 45 alpha (Gadd45a) is typically up-regulated by hepatotoxicants (Bartosiewicz et al. 2001) , which is in concordance with our data. The insulin-like growth factor binding protein 1 (Igfbp1) modulates IGF, which plays an essential role in the regulation of metabolism, growth, and development. Igfbp1 has been shown previously to be up-regulated after acute liver injury (Scharf et al. 2004) , again confirming the relevance of our highest ranked genes. The model created was used to predict the hepatotoxicity of two unknown compounds. UNC A was predicted to be hepatotoxic, which correlated well with the histopathological findings, a good pre-validation of our test system. The second unknown compound, UNC B, was predicted to be non-hepatotoxic, which correlated well with the lack of histopathological changes observed at 24h. Classification analysis based on our 24h model was able to predict UNC B to be hepatotoxic after 14 days of daily dosing (data not shown). This indicates that gene expression was affected by the compound after repeated dosage but not by a single dose.
Prediction of two unknown compounds
In conclusion, we have presented evidence that the accurate discrimination between acute hepatotoxic compounds and non-hepatotoxicants, based on their gene expression profiles was possible 24h post administration. A pre-validation with two unknown compounds showed that the model we created was able to predict acute hepatotoxicants. The use of this model for more chronic, repeat-dose toxicity is still unclear. Preliminary data from UNC B suggests that the model can predict hepatotoxicity at 2 weeks. Therefore, further work is needed to elucidate hepatotoxicity signatures for other end-points (e.g., repeated dose, other organ toxicity, and other species) and time points. Regarding the relatively small set of genes we conclude that focussed gene microarrays are sufficient to classify compounds with respect to acute hepatotoxicity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 de Longueville, F., Atienzar, F. A., Marcq, L., Dufrane, S., Evrard, S., Wouters, L., Leroux, F., Bertholet, V., Gerin, B., Whomsley, R., Arnould, T., Remacle, J., and Canning, M. (2003) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Steiner, G., Suter, L., Boess, F., Gasser, R., de Vera, M. C., Albertini, S., and Ruepp, S. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Yamada, Y., Webber, E. M., Kirillova, I., Peschon, J. J., and Fausto, N. (1998) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 where the larger a value is, the higher is the affinity of the two unknown compounds towards the respective group (scale, green = high affinity) and the classification marker indicates the class (hepatotoxic (red)/non-hepatotoxic (orange)) to which the two unknown compounds were assigned. 
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